-- Neuren Pharmaceuticals' (ASX:NEU) Nasdaq-listed partner, Acadia Pharmaceuticals, reported a 20% increase in first-quarter net sales of Rett syndrome drug Daybue to $101 million from $85 million in the previous corresponding period, according to a Thursday filing with the Australian bourse.
Neuren earned royalty income of $10.4 million in the first quarter, up 23% on the same time last year, the filing said.
Anticipated full-year royalties remain between $50 million and $54 million.
Additionally, Acadia maintained its full-year guidance for Daybue net sales of $460 million to $490 million, per the filing.
Neuren Pharmaceuticals shares rose 3% in midday trade on Thursday.